Novartis (NVS, $94.86) acquires IFM Tre, enlarges medicine portfolio
In a recent announcement, Novartis confirmed its acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC that specializes in developing anti-inflammatory medicines, especially the NLRP3 inflammasome. This latest acquisition will now add to the company’s immunomodulatory medicine portfolio.
Valued at $1.575 billion, according to the terms of the deal, Novartis would pay $310 million upfront and then become eligible to pay for as much as $1.265 billion in milestone payments.
The acquisition is a significant move for Novartis, as it gives it full exposure to IFM Tre's portfolio of NLRP3 inhibitors.
The NLRP3, the nucleotide-binding domain containing three pathway, is crucial to the body’s immune system and works as a warning sensor for pathogens signaling tissue damage and metabolic disorders.
The acquisition is significant as it means gaining control over IFM Tre's molecules that can selectively suppress inflammation caused by the NLRP3 inflammasome, while allowing the rest of the immune system to remain unaffected.
NVS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for NVS turned positive on June 11, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 11, 2026. You may want to consider a long position or call options on NVS as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
NVS moved above its 50-day moving average on June 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in of 341 cases, the price rose further within the following month. The odds of a continued upward trend are .
NVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 314 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for NVS crossed bearishly below the 50-day moving average on June 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.582) is normal, around the industry mean (19.401). P/E Ratio (21.930) is within average values for comparable stocks, (26.905). Projected Growth (PEG Ratio) (4.153) is also within normal values, averaging (15.807). Dividend Yield (0.031) settles around the average of (0.030) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (4.034).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care and nutritional products
Industry PharmaceuticalsMajor
Advertisement